NHS National Framework for Transition products commencing 1 February 2025
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 21 Jan 2025
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
United Kingdom: Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points
1 buyer
- NHS England Leeds
6 suppliers
- Sun Pharma Uxbridge
- Thornton & Ross Huddersfield
- Drreddys Laboratories Cambridge
- Zentiva Pharma London
- Biocon London
- Baxter Healthcare Norfolk
Description
Project title: NHS National Framework for Transition products commencing 1 February 2025Offer reference number: CM/TNS/24/5713Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.Potential periods of call-offs under the framework agreement:CM/TNS/24/5713/01 - Eribulin Injection, Bosutinib Tablets and Liraglutide InjectionLot 1 CESW: 01/02/2025 to 31/05/2026 (16 months)Lot 2 LSNE: 01/02/2025 to 31/05/2026 (16 months)Lot 3 NWLN: 01/02/2025 to 31/05/2026 (16 months)Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
Award Detail
1 | Sun Pharma (Uxbridge)
|
2 | Thornton & Ross (Huddersfield)
|
3 | Drreddys Laboratories (Cambridge)
|
4 | Zentiva Pharma (London)
|
5 | Biocon (London)
|
6 | Baxter Healthcare (Norfolk)
|
Renewal Options
Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months
Award Criteria
price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-04a41a
- FTS 002071-2025